Abstract
Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics. © Informa UK, Ltd.
Author supplied keywords
Cite
CITATION STYLE
Fink, K., & Shi, P. Y. (2014, February). Live attenuated vaccine: The first clinically approved dengue vaccine? Expert Review of Vaccines. https://doi.org/10.1586/14760584.2014.870888
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.